Avacta is the proprietary owner of Affimer technology for the development of biotherapeutics, diagnostic tests and research reagents. Affimers represent a radical alternative to antibody technology which dominates the drug industry. Avacta has made considerable progress towards its strategic goal to be ready to enter first-inman Affimer trials by the end of 2019. It is also using external collaborations to expand the opportunities for Affimer technology. Avacta has now announced a tieup with OncoSec Medical Inc to combine Affimers with the ImmunoPulse® electroporation technology to deliver Affimer therapies directly into tumours.